

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : <b>A61K 9/16</b>		A1	(11) International Publication Number: <b>WO 94/28879</b> (43) International Publication Date: 22 December 1994 (22.12.94)
(21) International Application Number: <b>PCT/GB94/01201</b> (22) International Filing Date: 2 June 1994 (02.06.94)		(81) Designated States: AU, CA, JP, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published <i>With international search report.</i>	
(30) Priority Data: <b>9311454.4 3 June 1993 (03.06.93) GB</b>			
(71) Applicant (for all designated States except US): BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL [GB/GB]; Central Office, Polaris House, North Star Avenue, Swindon SN2 1UH (GB).			
(72) Inventor; and (75) Inventor/Applicant (for US only): SMITH, Michael, Waddington [GB/GB]; 31 Rocks Lane, Barnes, London SW13 0DB (GB).			
(74) Agents: ROBERTS, Alison, Christine et al.; Kilburn & Strode, 30 John Street, London WC1N 2DD (GB).			
(54) Title: ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING A PROTEIN OR PEPTIDE, AN ANTIBODY AND POLYMERIC BEADS			
(57) Abstract  Pharmaceutical compositions for oral administration comprise a protein or peptide, an antibody which is specific for the protein or peptide and a plurality of polymer beads. The compositions enable proteins and peptides to be available by oral administration.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads.

5 The present invention relates to improved pharmaceutical compositions and, in particular, to compositions for oral administration containing biologically active materials, particularly peptides or proteins.

10 Proteins and peptides are used in the treatment of very many diseases or conditions and protein hormones such as insulin, calcitonin and growth hormones and also proteins such as erythropoietin, plasminogen activators and their precursors, interferons, interleukins and blood clotting factors are merely some of the numerous examples and, in addition, many compounds which are used as vaccines are 15 proteins or peptides.

20 However, although proteins and peptides are so widely used in medicine, they must generally be administered by intravenous or intramuscular injection since, even though they can be enterically coated so as to survive the conditions of the stomach, they are not easily adsorbed through the gut wall. Injection is not a popular route of administration with patients and this often leads to poor patient compliance. In addition, with conditions 25 such as diabetes where daily injections have to be given, problems often arise because of the necessity of injecting many times in the same area. In order to overcome these problems, it would be helpful to develop ways of administering these compounds via the oral route 30 since this is the simplest and most popular route with patients.

There have been many attempts to enable proteins and peptides to be administered orally and these have

5 included various formulations in which the protein or peptide is encapsulated in liposomes or formulations including penetration enhancers. However, liposomes are often unreliable and penetration enhancers may increase the uptake of unwanted substances as well as the substances on which they are intended to act.

10 WO-A-8705505 discloses oral compositions of insulin coated onto particles and covered with a lipid coat. JP-A-55017328 discloses water-in-oil-in-water emulsions containing insulin and intended for oral administration.

15 However, the present inventor has adopted a completely different approach from any which has previously been used and has discovered that it is possible to make use of M cells as a route for peptide absorption from the gut lumen into the body.

20 M cells occur in the epithelial lining of the Peyer's patch lymphoid follicles of the intestine. They are epithelial cells which, probably because of their proximity to lymphoid tissue, are rudimentary and, therefore, more easily penetrated by macromolecules than epithelial cells elsewhere in the intestine. Therefore, 25 although the intestine is generally designed to resist particle penetration in order to protect against infection, the M cells are able to endocytose small amounts of particulate matter from the gut lumen for presentation to the gut associated lymphoid tissue (GALT). This enables the gut immune system to respond to undesirable antigens present in the gut lumen (Neutra and Kraehenbuhl, *Trends in Cell Biology*, 2, 134-138 (1992)).

30 The function and mode of action of M cells have been

extensively studied and semi-quantitative estimates of M cell ability to adsorb particles from intestinal loops were first carried out using fluorescent microspheres. From this work it was suggested that these beads might 5 prove useful in studying antigen uptake adsorbed onto polystyrene microparticles (Pappo and Ermak, *Cellular and Experimental Immunology*, 76, 144 (1989)). It was subsequently found that coating particles with an anti-M-cell IgM antibody causes a three fold increase in bead 10 uptake (Pappo et al., *Immunology*, 73, 277 (1991)). In addition, it was shown that IgA raised against mammary tumour virus increased the binding of the IgA-virus complex to the M cell surface and IgG inhibited the binding. (Weltsin et al., *J. Cell Biol.*, 108, 1673 15 (1989)). More recent work has shown IgA-coated beads to bind four times more readily and to be taken up twenty times more readily than beads coated with albumin (Porta et al., *Exp. Physiol.*, 77, 929 (1992)). It has therefore been concluded that IgG, IgA and IgM binding to beads 20 and/or particles can be expected to increase the binding of the beads or particles and their uptake by M cells.

However, although it has been suggested in the past that M cells might be useful as a route for the absorption of 25 macromolecules (O'Hagan, *Advanced Drug Delivery Reviews*, 5, 265-285 (1990)), this idea has not been developed further and all of the recent work concerning the transporting of beads into M cells has been concentrated on the binding of beads to M cells as a model for 30 antigens which it is normally the function of M cells to take up and process. The idea of using M cells as a possible route by which proteins and peptides could pass from the gut lumen into the body seems not to have been afforded serious consideration, possibly because of

anticipated problems in transporting macromolecules out of M cells into the lymphatic system.

Recent work on M cells has concentrated on the coating of 5 beads or particles with immunoglobulins raised against some component of the M cell surface. However, in an attempt to use the M cells to direct proteins or peptides from the gut lumen into lymphoid tissue, the present inventor has adopted an alternative approach.

10

In a first aspect of the present invention, there is provided a pharmaceutical or veterinary composition for oral administration, the composition comprising a biologically active material, an antibody which binds 15 specifically to the material and a plurality of polymer beads.

20

The theory behind the use of such a composition is that an antibody raised against a biologically active peptide or protein will not only bind specifically to that peptide or protein but will also bind non-specifically to the M cell surface so allowing a bead or particle carrying the peptide or protein and the antibody to be carried into and across M cells. The dual action of 25 specific binding to the active peptide or protein and non-specific binding to the M cell surface should preserve the selectivity of the absorption whilst increasing the gut permeability in an immunoglobulin non-selective manner. It should be stressed, however, that 30 the efficacy of the invention is in no way affected by the correctness or otherwise of this theory.

As briefly mentioned above, it might have been expected that even if beads or particles could be transported into

5 M cells, they would remain there and would not pass out of the M cells into the lymphatic system. Surprisingly, however, it now seems that this is not a major problem and that it is possible to gain access to the lymphatic system via M cells.

10 The greatest advantage of the composition of the present invention is, of course, that it makes possible the oral administration of biologically active materials. However, a further advantage is that, from the M cells, the peptide or protein will pass into the lymphatic system rather than into the blood and this may mean that bioavailability is increased because hepatic first pass metabolism will be avoided. In addition, the composition 15 of the present invention is relatively inexpensive and easy to prepare.

20 The term 'biologically active material' includes pharmaceutically active materials and materials which modify biological function, particularly proteins and peptides and also molecules comprising proteins or peptides, for example, glycoproteins which contain both protein and sugar residues. Other biologically active materials which may be present in the compositions 25 include nucleic acids, for example oligonucleotides such as antisense oligonucleotides which may be useful for interfering with the replication of nucleic acids in virally infected or cancerous cells and for correcting other forms of inappropriate cell proliferation. Polysaccharides such as heparin are also suitable for 30 inclusion in the compositions as are combinations of one or more protein, nucleic acid or polysaccharide.

The material may be useful in human or veterinary

medicine and may be used either for the treatment or the prophylaxis of diseases. Alternatively, the materials may be useful for cosmetic or for diagnostic purposes.

5 When the biologically active material is a protein or peptide, it may be a substance which occurs naturally in the human or animal body, for example, a protein hormone such as insulin, calcitonin or a growth hormone or a protein such as erythropoietin, plasminogen activators 10 and their precursors, for example, t-PA urokinase, pro-urokinase and streptokinase, an interferon, for example, human interferon- $\alpha$ , or an interleukin such as IL-1, IL-2, IL-3, IL-4 or IL-5 a blood factor such as factor VIII.

15 Alternatively, the protein or peptide may be intended as a vaccine, in which case it will be antigenic and may be all or part of a protein derived from a pathogenic organism, for example a bacterial protein or a viral coat 20 protein. In either case, the protein or peptide may be isolated from natural sources, produced by genetically modified organisms or may be wholly or partially synthesised by automated means.

25 For vaccines, it is a particular advantage that when the composition of the invention is used, the biologically active material is passed directly into the lymphoid tissue since it is quickly available to the immune system which can then raise antibodies specific for the 30 administered peptide or protein and thereby give the body immunity against the organism from which the peptide or protein is derived.

The antibody may be of the IgG, IgA or IgM isotype although IgG is preferred. As mentioned above, it is

specific for the biologically active material and may be prepared by conventional means. Methods for raising antibodies are well known to those skilled in the art.

5       The biologically active material will generally be adsorbed onto the surface of the beads and the antibody is added so as to form a complex between the material and the antibody and to leave part of the antibody free for non-specific binding to the M cells. Perhaps one of the  
10      most surprising aspects of the present invention is that it is not necessary to add the active material and the antibody in equal quantities to the surface of the beads. Instead, it is possible to use a considerable excess of  
15      the active material and this, of course, allows a greater amount of the material to be endocytosed with the beads than would have been expected.

20      The ratio of active material to antibody may vary considerably but may be from as high as about 750:1 to 1:1. More generally, the ratio will be from about 500:1 to 10:1 and a typical value is about 100:1.

25      The beads may be either solid or hollow and may, optionally, be biodegradable. Biodegradable beads can be prepared from homo- or co-polymers of naturally occurring materials and examples of such polymers include poly(D,L-lactide-co-glycolides) in which the proportions of lactide and glycolide can be varied according to the exact properties of which are required. Biologically  
30      active materials such as proteins may be incorporated into biodegradable beads, for example in the cavities of hollow beads, and will be released when the beads break down. The beads may be chosen to break down after a predetermined time - for example after the beads have

passed through the M cells into the lymphatic system.

5 The beads are made from a non-immunogenic polymeric material such as polystyrene, latex or other polymers and range from 0.05  $\mu\text{m}$  to 10  $\mu\text{m}$  in diameter. A particularly suitable diameter of bead is from 0.1 to 1.5  $\mu\text{m}$ .

10 Suitable beads may be obtained from Polysciences, Inc. (400 Valley Road, Warrington, PA18976, USA).

15 The composition may be formulated as tablets and may contain other excipients, for example fillers, binders or colouring or flavouring agents. However, because the composition takes the form of beads, it is preferred that it is packed into capsules which may be of either the hard shelled or the soft shelled type.

20 Preferably the composition is enteric coated to enable it to pass through the stomach without being broken down in order that the greatest possible number of beads should reach the Peyer's patch tissue. Suitable enteric coating materials are well known to those skilled in the art.

25 The dosage of the composition may easily be determined by one skilled in the art and will be similar to the dosages of proteins and peptides which are, at present, administered by other routes.

30 In a second aspect of the present invention, there is provided a process for the preparation of a pharmaceutical composition according to the first aspect, the process comprising adsorbing a biologically active material onto polymer beads and reacting the material with an immunoglobulin which binds specifically to it.

5       The steps may be carried out in either order - that is an antibody complex may be prepared and then adsorbed on the surface of the beads or, alternatively, the biologically active material may be adsorbed onto the surface of the beads, following which, the beads are incubated with an immunoglobulin which binds specifically to the peptide or protein. In general, however, it is preferred that the beads be incubated with the biologically active material, washed to remove unbound material and then separately  
10      incubated with the antibody.

15      The amount of biologically active material which is adsorbed onto the surface of the beads varies depending on the concentration of the active material in the solution in which the beads are incubated. It has been found that a suitable concentration of the active material is from about 3 to about 10 mg/ml and preferably from 4 to 6 mg/ml. For proteins such as bGH, bSA and hIgG, it has been found that saturation of the beads is  
20      achieved using solutions of concentration greater than about 5 mg/ml.

25      The amount of biologically active material which is adsorbed also, of course, depends on the size of the beads used. Clearly, the smaller the beads, the larger the surface area per unit weight of bead.

30      When the above described method of preparing the formulation is used, it may be necessary to incubate the beads a second time in a solution of active material before incubation with the antibody solution in order to increase the amount of active material adsorbed onto the surface of the beads. If this second incubation step is used, it is often useful to use a much higher

concentration of active material in the incubation solution and a suitable concentration may be, for example from 30 to 80 mg/ml, typically about 50 mg/ml.

5 The process may include the additional steps of encapsulating the beads and coating with an enteric coat.

10 The invention will now be further described with reference to the following examples and to the accompanying drawing.

15 FIGURE 1 is a plot of the amount of protein which binds to a fixed number of beads against the concentration of protein in the incubation solution.

Example 1

**Preparation of Coated Beads**

20 FLUORESBRITE<sup>™</sup> polystyrene plain 0.5  $\mu\text{m}$  microspheres (Polysciences, Inc, No 17152, yellow-green and No 19507, red) were incubated separately in pH 11.0 buffer adjusted to pH 7.4 in the presence of 5 mg/ml bovine serum albumin (bSA), human immunoglobulin G (hIgG) or bovine growth 25 hormone (bGH) for 90 min at 37°C. Protein coated beads were then washed twice with phosphate buffered saline and unbound surface sites blocked by a second incubation in a 50 mg/ml solution of bSA for 30 min at 37°C. These beads were then washed three times in phosphate buffered 30 saline before further use. Binding specific IgG antibody raised against bGH to the bGH coated beads involved a further incubation with this antibody for 3 hr at 37°C. Attachment of the antibody to bGH was verified, in separate experiments, by estimating the amount of  $\text{I}^{125}$ .

labelled antibody bound to similar bGH-coated beads.

5 Suspensions of red or yellow-green protein beads coated with different proteins were then mixed, in equal proportions, to produce a final suspension containing  $7.2 \times 10^{11}$  beads/ml for instillation into mouse intestinal loops containing Peyer's patch tissue.

10 Experiments to optimise the amount of protein bound to the beads in the first incubation were carried out and a plot of bound protein against protein concentration in the incubation solution was prepared in order to calculate the optimum protein concentration to be used. This plot is shown in Figure 1. Incubation of  $0.5 \mu\text{m}$  beads was carried out using three different proteins, 15 bGH, bSA and hIgG in solutions of concentration varying from 1 to 10 mg/ml. For a standard number of  $3.65 \times 10^{11}$   $0.5 \mu\text{m}$  beads, it was found that the maximum amount of protein which could be bound varied from about 0.2 to 1.5 20 mg and that saturation of the beads was achieved using solutions of concentration greater than about 5 mg/ml.

#### Example 2

##### 25 **Absorption of Beads Into M Cells**

Eight-to-ten week old Balb/c mice were anaesthetized with 0.4 ml avertin (2.5% w/v) injected intraperitoneally and closed loops of distal ileum formed containing  $7.2 \times 10^{11}$  30 beads per ml of Krebs-Henseleit buffer, pH 7.4. Peyer's patch tissue removed from these loops 45 min later was then rinsed in buffer and fixed in 4% v/v glutaraldehyde. This tissue was then stained with 5% w/v propidium iodide to aid later identification of M cells using confocal

microscopy. Confocal images taken serially at 4  $\mu$ m intervals through the epithelium were captured under conditions enabling red and yellow-green fluorescent beads to be counted separately. It was also possible, 5 using this method, to count the number of beads binding to the surface of M cells separately from those which had already entered M cells.

10 Experiments were carried out to study the interaction of microbeads with mouse intestinal M cells. Three different experiments were carried out. In the first experiment, the uptake of free bovine growth hormone (bGH) was compared with the uptake of bovine serum albumen (bSA). In the second experiment, the uptake of 15 bSA was compared with the uptake of human immunoglobulin (hIgG) and in the third experiment, the uptake of free bGH was compared with the uptake of bGH bound to a specific antibody. The results obtained from this experiment are set out in Tables 1 and 2 below.

20

Table 1.

Experiment	Surface Binding		
	bGH	bSA	bSA/bGH
1	188 $\pm$ 57 (8)	296 $\pm$ 79 (8)	1.7 $\pm$ 0.1 (8)
25	bSA 39 $\pm$ 15 (8)	hIgG 117 $\pm$ 27 (8)	hIgG/bSA 5.4 $\pm$ 1.8 (8)
2	bGH 234 $\pm$ 70 (8)	bGH-Ab 436 $\pm$ 61 (8)	bGH-Ab/bGH 3.3 $\pm$ 0.6 (8)
3			

Table 2

Experiment		Cellular Uptake		
5	1	bGH 45 ± 14 (8)	bSA 84 ± 22 (8)	bSA/bGH 2.2 ± 0.4 (8)
	2	BSA 28 ± 10 (8)	hIgG 102 ± 62 (8)	hIgG/BSA 5.7 ± 1.1 (8)
	3	bGH 39 ± 13 (8)	bGH-Ab 214 ± 44 (8)	bGH-Ab/bGH 9.5 ± 2.0 (8)

10 All of the values given in Tables 1 and 2 are means ± SEM estimated over  $3 \times 10^4 \mu\text{m}^2$  of intestinal follicle surface. The values given in brackets represent the number of follicles analysed.

15 The ratios given in Tables 1 and 2 were calculated separately for each follicle analysed and so do not correspond exactly to the ratio of the figures in the first and second columns.

20 The first experiment shows that beads coated with bSA bind to and enter M cells about twice as readily as those coated with bGH after both sets of beads have been presented simultaneously to the same piece of tissue in an intestinal loop. The second experiment shows that,

25 under identical conditions, beads coated with hIgG bind and enter M cells over five times more readily than beads coated with bSA. This type of non selective effect has been seen previously using IgG, IgA and IgM proteins.

5 The third experiment shows that beads coated with bGH to which a specific antibody is later bound is taken up about ten times more readily than are beads coated with bGH alone even though the increased efficiency of binding is only three-fold. This was a most unexpected result and the mechanism leading to this selective increase in cell uptake remains unknown.

10 The statistical significance of the results shown in Tables 1 and 2 was assessed and the results of this assessment are shown in Table 3.

Table 3

15

P values (two-tailed paired t-test)

Testing	Surface binding	Cellular uptake	selectivity
1. bSA > bGH	0.003	0.029	0.178 (NS)
2. hIgG > bSA	0.007	0.000	0.078 (NS)
3. bGH-Ab > bGH	0.001	0.000	0.009

Table 3 indicates the statistical significance of protein selective effects on microbead binding and uptake by mouse intestinal M cells.

5 The following results are indicated:

Surface binding: bGH < bSA < hIgG; bGH < bGH-Ab

Cellular uptake: bGH < bSA < hIgG; bGH < < bGH-Ab

10 Selectivity: uptake > binding: bGH = bSA = hIgG; bGH < < bGH-Ab. (NS) = not statistically significant.

5 The experimental protocol employed allows one to assess the significance of differences reported in Table 1 using a paired t-test. This in turn removes any error that could occur through animal or tissue variation. All of the protein dependent differences in bead binding and uptake were statistically significant and the additional increase in bead uptake conferred by binding a specific antibody to bGH was also found to be statistically significant ( $P = 0.009$ ).

10

From the results of the above experiments, it can be seen that the amount of protein entering the M cells is significantly increased when antibody complexed to the protein is adsorbed onto the beads.

15

Example 3

**Movement of Beads Through M Cells**

20 The experiment described in Example 2 was repeated using rats rather than mice. In this experiment, 1 ml of phosphate buffered saline (PBS) containing  $7.2 \times 10^{11}$  beads per ml was instilled into the proximal gut lumens of 11 rats. The gut contents were then allowed to flow 25 distally under as nearly physiological conditions as possible.

30 In five of the rats, Peyer's patch tissue removed from the gut lumen after 90 minutes was rinsed and stained before taking confocal images at 4  $\mu\text{m}$  intervals through the epithelium in order to determine the number of beads binding to M cells and the number of beads which had already entered the M cells.

5 In the remaining six rats, the mesenteric lymph ducts were cannulated before instilling the bead suspension into the proximal gut lumen and samples of lymph were taken at 5 minute intervals for 90 minutes. The samples were then scanned using a fluorescent sorter (FACS analysis) to determine the presence of red and green beads.

10 In this experiment, the uptake and throughput of free bovine growth hormone (bGH) was compared with similar results for bGH bound to a specific antibody (bGH-Ab). The results are presented in Table 4.

Table 4

15	Ratio GH-Ab:GH	Method	Result
	Cell Surface Binding	Confocal	3.1 ± 0.6 (5)
	Cellular Uptake	Confocal	5.0 ± 0.3 (5)
	Entering Lymph	FACS Analysis	2.9 ± 0.4 (6)

20 The results presented in Table 4 confirm the results of Example 2 by showing once again that beads coated with bGH to which a specific antibody is later bound will bind to M cells more efficiently than beads coated with bGH alone. Furthermore, the uptake of the bGH-Ab coated beads is even more significant with, in this case, about five times as many bGH-Ab coated beads entering M cells as bGH coated beads. The results also show, however, that about three times as many beads coated with bGH-Ab reached the lymphatic system as beads coated with bGH alone. This suggests that the bioavailability of a pharmaceutically active substance would be significantly

improved by its inclusion in a composition according to the present invention because the active substance is able to pass preferentially into the lymphatic system thus avoiding first pass metabolism which occurs if 5 active substances are absorbed into the hepatic portal vein and are passed directly to the liver.

CLAIMS

1. A pharmaceutical or veterinary composition for oral administration, the composition comprising a biologically active material, an antibody which binds specifically to the biologically active material and a plurality of polymer beads.  
5
2. A pharmaceutical composition as claimed in claim 1, wherein the biologically active material is a peptide or protein.  
10
3. A composition as claimed in claim 2, wherein the protein or peptide is one which occurs naturally in the human or animal body for example a protein hormone such as insulin, calcitonin or a growth hormone or a protein such as erythropoietin, plasminogen activators and their precursors, for example, t-PA urokinase, pro-urokinase and streptokinase, an interferon, for example, human interferon- $\alpha$ , or an interleukin such as IL-1, IL-2, IL-3, IL-4 or IL-5 a blood factor such as factor VIII.  
15
4. A composition as claimed in claim 2, wherein the protein or peptide is for used as a vaccine and comprises all or part of a protein derived from a pathogenic organism.  
20
5. A composition as claimed in any one of claims 1 to 4 wherein the antibody is of the IgG isotype.  
25
6. A composition as claimed in any one of claims 1 to 5 wherein the beads are made from polystyrene.  
30
7. A composition as claimed in any one of claims 1 to

5 wherein the beads range in size from 0.5  $\mu\text{m}$  to 10  $\mu\text{m}$ .

8. A composition as claimed in any one of claims 1 to  
5 wherein the active material and the antibody form a  
complex and wherein the complex is adsorbed onto the  
surface of the beads.

9. A composition as claimed in any one of claims 1 to  
10 8, wherein the ratio of active material to antibody is  
from 750:1 to 1:1.

10. A composition as claimed in any one of claims 1 to  
9 wherein the beads are biodegradable.

15 11. A composition as claimed in claim 10 wherein the  
biodegradable beads contain additional protein or  
peptide.

20 12. A composition as claimed in any one of claims 1 to  
11 which has an enteric coat.

25 13. A process for the preparation of a pharmaceutical  
composition comprising a biologically active material, an  
antibody which binds specifically to the active material  
and a plurality of polymer beads, the process comprising  
adsorbing the biologically active material onto the  
polymer beads and reacting the material with the  
antibody.

30 14. A process as claimed in claim 13 in which the  
biologically active material is reacted with the antibody  
before adsorption onto the beads.


15. A process as claimed in claim 13 in which the

biologically active material is reacted with the antibody after adsorption onto the beads.

16. A process as claimed in any one of claims 13 to 15,  
5 further comprising enterically coating the composition.

1 / 1

FIGURE 1



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 94/01201A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61K9/16

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 17167 (BIOTECH AUSTRALIA PTY) 15 October 1992	1-3, 6-11, 13-15.
Y	see the whole document ----	4,5
Y	EP,A,0 238 396 (LURHUMA, ZIRIMWABAGABO) 23 September 1987 see page 3, line 13 - line 20 see page 4, line 4 - line 17 see page 7, line 11 - page 8, line 3 -----	4,5

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

1

Date of the actual completion of the international search

2 September 1994

Date of mailing of the international search report

20.09.94

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentstaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Ventura Amat, A

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 94/01201

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9217167	15-10-92	AU-A-	1558092	02-11-92
		EP-A-	0531497	17-03-93
		NZ-A-	242220	27-04-94
EP-A-0238396	23-09-87	FR-A-	2595826	18-09-87
		FR-A-	2625100	30-06-89
		JP-A-	63033660	13-02-88
		OA-A-	8498	29-07-88